DE69701258T2 - Verwendung von benzonaphtalene-derivaten zur herstellung eines arzneimittels zur behandlung von krankheiten des nervensystems - Google Patents

Verwendung von benzonaphtalene-derivaten zur herstellung eines arzneimittels zur behandlung von krankheiten des nervensystems

Info

Publication number
DE69701258T2
DE69701258T2 DE69701258T DE69701258T DE69701258T2 DE 69701258 T2 DE69701258 T2 DE 69701258T2 DE 69701258 T DE69701258 T DE 69701258T DE 69701258 T DE69701258 T DE 69701258T DE 69701258 T2 DE69701258 T2 DE 69701258T2
Authority
DE
Germany
Prior art keywords
treatment
diseases
nervous system
benzonaphtalene
pct
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69701258T
Other languages
English (en)
Other versions
DE69701258D1 (de
Inventor
Xavier Vige
Jesus Benavides
Braham Shroot
Veronique Taupin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Galderma Research and Development SNC
Original Assignee
Galderma Research and Development SNC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galderma Research and Development SNC filed Critical Galderma Research and Development SNC
Application granted granted Critical
Publication of DE69701258D1 publication Critical patent/DE69701258D1/de
Publication of DE69701258T2 publication Critical patent/DE69701258T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
DE69701258T 1996-04-05 1997-04-02 Verwendung von benzonaphtalene-derivaten zur herstellung eines arzneimittels zur behandlung von krankheiten des nervensystems Expired - Fee Related DE69701258T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9604359A FR2747041B1 (fr) 1996-04-05 1996-04-05 Utilisation de derives benzonaphtaleniques pour la fabrication de medicaments destines au traitement des neuropathies
PCT/FR1997/000590 WO1997037648A1 (fr) 1996-04-05 1997-04-02 Utilisation de derives benzonaphtaleniques pour la fabrication de medicaments destines au traitement des maladies du systeme nerveux

Publications (2)

Publication Number Publication Date
DE69701258D1 DE69701258D1 (de) 2000-03-09
DE69701258T2 true DE69701258T2 (de) 2000-12-21

Family

ID=9490993

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69701258T Expired - Fee Related DE69701258T2 (de) 1996-04-05 1997-04-02 Verwendung von benzonaphtalene-derivaten zur herstellung eines arzneimittels zur behandlung von krankheiten des nervensystems

Country Status (23)

Country Link
US (1) US6043280A (de)
EP (1) EP0900078B1 (de)
JP (1) JP2000512619A (de)
KR (1) KR20000005179A (de)
CN (1) CN1221341A (de)
AT (1) ATE189385T1 (de)
AU (1) AU717704B2 (de)
BR (1) BR9708511A (de)
CA (1) CA2250755A1 (de)
CZ (1) CZ317698A3 (de)
DE (1) DE69701258T2 (de)
ES (1) ES2144857T3 (de)
FR (1) FR2747041B1 (de)
GR (1) GR3033061T3 (de)
HU (1) HUP9902167A3 (de)
NO (1) NO984651L (de)
NZ (1) NZ332158A (de)
PL (1) PL329219A1 (de)
PT (1) PT900078E (de)
RU (1) RU2160098C2 (de)
SK (1) SK133398A3 (de)
WO (1) WO1997037648A1 (de)
ZA (1) ZA972875B (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO2178B1 (en) 1999-10-19 2003-04-23 اف . هوفمان لاروش ايه جي Treatment of invasive diseases, using selected anti-PAR materials
WO2001034633A2 (en) * 1999-11-12 2001-05-17 Fred Hutchinson Cancer Research Center Methods for treatment of human huntington's disease and methods of screening for active agents
US6914074B2 (en) * 2001-12-13 2005-07-05 Wyeth Substituted phenyl naphthalenes as estrogenic agents
UA77526C2 (en) * 2002-06-07 2006-12-15 Sanofi Aventis Substituted derivatives of 1-piperazineacylpiperidine, a method for the preparation thereof and their use in therapy
DK2613776T3 (da) 2010-09-01 2020-10-19 Univ Jefferson Sammensætning og fremgangsmåde til muskelreparation og -regenerering
KR101981930B1 (ko) 2017-08-10 2019-05-27 주식회사 에니텍시스 랜딩 장치

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5455248A (en) * 1993-09-14 1995-10-03 Sterling Winthrop Inc. Substituted 6,11-ethano-6,11-dihydrobenzo[b] quinolizinium salts, and compositions and method of use thereof

Also Published As

Publication number Publication date
EP0900078A1 (de) 1999-03-10
WO1997037648A1 (fr) 1997-10-16
NO984651L (no) 1998-12-03
US6043280A (en) 2000-03-28
AU717704B2 (en) 2000-03-30
PT900078E (pt) 2000-07-31
RU2160098C2 (ru) 2000-12-10
SK133398A3 (en) 1999-12-10
NO984651D0 (no) 1998-10-05
NZ332158A (en) 2000-06-23
CZ317698A3 (cs) 1999-02-17
HUP9902167A2 (hu) 2000-04-28
BR9708511A (pt) 1999-08-03
ES2144857T3 (es) 2000-06-16
HUP9902167A3 (en) 2000-07-28
DE69701258D1 (de) 2000-03-09
PL329219A1 (en) 1999-03-15
FR2747041A1 (fr) 1997-10-10
FR2747041B1 (fr) 1998-05-22
AU2392797A (en) 1997-10-29
ATE189385T1 (de) 2000-02-15
KR20000005179A (ko) 2000-01-25
CA2250755A1 (fr) 1997-10-16
JP2000512619A (ja) 2000-09-26
GR3033061T3 (en) 2000-08-31
CN1221341A (zh) 1999-06-30
EP0900078B1 (de) 2000-02-02
ZA972875B (en) 1997-10-31

Similar Documents

Publication Publication Date Title
ATE205086T1 (de) Verwendung von dem chelatbildner clioquinol zur herstellung eines arzneimittelszur behandlung von alzheimerschen krankheit
ATE332702T1 (de) Verwendung von glu-trp dipeptiden zur herstellung eines arzneimittels zur behandlung von verschiedenen gefässneubildung-assozierten erkrankungen
ATE321548T1 (de) Verwendung von statin zur behandlung von hauterkrankungen
DE69526937D1 (de) Verwendung von methanbisphosphonsäurederivaten zur behandlung von aufgelockerten prothesen
DE59508961D1 (de) Verwendung von weihrauch zur behandlung der alzheimer-krankheit
ATE252897T1 (de) Verwendung von p-aminophenolderivaten zur herstellung von pharmazeutischen zusammensetzungen zur behandlung von neurodegenerativen erkrankungen
DE69711078T2 (de) Topische verwendung von kappa-opioidrezeptoragonisten zur behandlung von augenschmerz
DE69820480T2 (de) Verwendung von wenigsten einem fukan zur herstellung eines arzneimittels für die behandlung pariodontaler erkrankungen
DE69805305D1 (de) Verwendung von phanquinon zur behandlung von alzheimer's krankheit
ATE189385T1 (de) Verwendung von benzonaphtalene-derivaten zur herstellung eines arzneimittels zur behandlung von krankheiten des nervensystems
ATE190839T1 (de) Verwendung von prodelphidinen zur behandlung von arthrose
HUP0100611A2 (hu) Triazin vegyületek, és ilyeneket tartalmazó gyógyszerkészítmények a központi idegrendszer elváltozásainak kezelésére
DE69626916T2 (de) Sertralin zur Behandlung von Post-Myocard-Infarkt-Patienten
NZ320522A (en) Piperazinylalkylthiopyrimidine derivatives, pharmaceutical compositions containing the same and a process for the preparation of the compounds
ATE192650T1 (de) Verwendung von efaroxan und dessen derivaten zur herstellung eines arzneimittels zur behandlung parkinsonscher krankheit
ATE186640T1 (de) Verwendung von efaroxan und dessen derivaten zur herstellung eines arzneimittels zur behandlung neurogenerativer erkrankungen
DE69620394D1 (de) Verwendung von forskolin oder diese enthaltende extrakte zur herstellung eines medikaments für die behandlung von alkoholsucht
ATE312611T1 (de) Verwendung von mizolastine zur herstellung eines arzneimittels zur behandlung von entzündungen
ATE232098T1 (de) Verwendung von efaroxan zur herstellung eines arzneimittels zur behandlung von huntington krankheit
ATE94558T1 (de) Sialosylcholesterol, verfahren zu dessen herstellung und arzneimittel zur behandlung von krankheiten des nervensystems.

Legal Events

Date Code Title Description
8332 No legal effect for de
8370 Indication related to discontinuation of the patent is to be deleted
8339 Ceased/non-payment of the annual fee